Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Catherine McCarthy

Family Medicine Reno, NV Medical Doctor

NPI 1386600419 CMS profile 1114597

123 - 17Th Street Mail Stp #316, Reno, NV 89557

Open in the dashboard

General payments

$68,474

79 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Catherine McCarthy of Reno, NV is reported in the CMS Open Payments database as having received $68,474 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,739 19
2024 General $6,875 5
2023 General $12,835 14
2022 General $20,842 27
2021 General $10,702 12
2020 General $1,375 1
2019 General $105 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine McCarthy
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Catherine McCarthy were reported at $15,739. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Catherine McCarthy Family Medicine median Middle half National median
2019 $105 $150 $41–$543 $163
2020 $1,375 $120 $32–$415 $114
2021 $10,702 $137 $35–$551 $132
2022 $20,842 $137 $37–$512 $149
2023 $12,835 $149 $42–$545 $160
2024 $6,875 $156 $44–$560 $164
2025 $15,739 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $49,452 53 payments
  2. Merck Sharp & Dohme Corporation $18,921 25 payments
  3. Edwards Lifesciences Corporation $100 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $45,113 44 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,000 8 payments
  3. Consulting Fee $9,045 5 payments
  4. Travel and Lodging $2,678 9 payments
  5. Food and Beverage $638 13 payments
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $42,521 47 payments
  2. NEXPLANON Womens Health $7,021 8 payments
  3. Nexplanon Womens Health $4,181 4 payments
  4. ENFLONSIA $2,600 10 payments
  5. VARIVAX $2,600 10 payments
  6. RECOMBIVAX HB $2,600 10 payments
  7. GARDASIL $105 1 payment
  8. SAPIEN 3 Ultra RESILIA $100 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

257

Median for Family Practice: 1,826

Drug cost

$3,797

Median for Family Practice: $120,094

Branded share of claims

0%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mexiletine Hcl Generic 12 $1,064
Levothyroxine Sodium Generic 59 $866
Atorvastatin Calcium Generic 42 $630
Lovastatin Generic 22 $299
Rosuvastatin Calcium Generic 18 $176
Metformin Hcl Generic 21 $175
Lisinopril Generic 22 $166
Olmesartan Medoxomil Generic 13 $101
Tamsulosin Hcl Generic 12 $96
Hydrochlorothiazide Generic 11 $90

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$11,593

Medicare's payments for the services billed

Medicare patients

86

Average age 70

Services billed

172

49 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 37%
Ischemic heart disease 34%
Depression 28%
Diabetes 27%
Chronic kidney disease 26%
COPD 23%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record